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Juvenile idiopathic arthritis - one of the most common
rheumatic disease in children (1:1000) [Timothy Beukel-
man et all, 2011]. The most effective basic drug is meth-
otrexate, an initial dose of 15 mg/m2/week. Our study
to determine the concentration of methotrexate in
serum aims to develop a test system to clarify the rea-
sons for lack of efficacy of methotrexate in some
patients. The study currently includes 46 children (19
boys (41,3%), 27 girls (58.7%)) with different forms of
JIA, according to the classification of ILAR. Systemic
arthritis – 9 children (20%), arthritis oligoarticular – 9
(20%), polyarticular arthritis – 15 (34%), psoriatic arthri-
tis – 1 (2%), arthritis entesitis – 11 (24%). Of the 46
children noone is in clinical remission off medication.
26 (56.5%) children met the criteria of inactive disease.
Results of determining the concentration of metho-
trexate in children with JIA were distributed as follows -
0-1 umol/l - 2,18%; 1-1,5 umol/l - 34.78%; 1,5-2 umol/l
- 17.39 % 2-2,5 umol/l - 32.61%; 2,5-3 umol/l - 8.69%
above 3 umol/l - 4,35%. Among children with the results
of the concentration of methotrexate up to 1.5 umol/l -
88.24% have signs of active disease (elevated ESR / CRP
high / dysproteinemia / active joints). Low concentra-
tions of methotrexate in 73.3% are associated with high
levels of ESR and CRP. Among children with the results
of methotrexate concentration above 1,5 umol/l signs of
active disease manifestations are much rarer in 48,28%
of cases.
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